NASDAQ:ONVO - Organovo Stock Price, Forecast & News

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Organovo Holdings Inc (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The medical research company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 69.36%. View Organovo's Earnings History.

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Organovo.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.

Headlines about ONVO stock have been trending very negative on Tuesday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Organovo.

Organovo saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,580,000 shares, an increase of 6.8% from the January 15th total of 1,480,000 shares. Based on an average trading volume of 726,000 shares, the short-interest ratio is currently 2.2 days. Currently, 1.2% of the company's shares are short sold. View Organovo's Current Options Chain.

Some companies that are related to Organovo include Windtree Therapeutics (WINT), Solid Biosciences (SLDB), Dyadic International (DYAI), Fennec Pharmaceuticals (FENC), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Gamida Cell (GMDA), Axcella Health (AXLA), Surface Oncology (SURF), Cidara Therapeutics (CDTX), Applied Genetic Technologies (AGTC), Champions Oncology (CSBR), Pharmacyte Biotech (PMCB), Pluristem Therapeutics (PSTI) and Acorda Therapeutics (ACOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), Aerojet Rocketdyne (AJRD), NVIDIA (NVDA), Blackstone Group (BX), LADENBURG THALM/SH SH (LTS), Exelixis (EXEL), Anavex Life Sciences (AVXL), Micron Technology (MU), Novavax (NVAX) and General Electric (GE).

Organovo's stock is owned by many different of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (14.95%), Renaissance Technologies LLC (5.38%), Essex Investment Management Co. LLC (1.01%) and UBS Group AG (0.07%). View Institutional Ownership Trends for Organovo.

ONVO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Organovo.

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Renaissance Technologies LLC and ARK Investment Management LLC. View Insider Buying and Selling for Organovo.

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ONVO stock can currently be purchased for approximately $0.31.

Organovo has a market capitalization of $40.49 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.

The official website for Organovo is http://www.organovo.com/.

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]